| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0091270008315310 |
| P698 | PubMed publication ID | 18303127 |
| P50 | author | Christopher D Payne | Q37829093 |
| P2093 | author name string | Govinda J Weerakkody | |
| David S Small | |||
| Kenneth J Winters | |||
| Nagy A Farid | |||
| Ying G Li | |||
| Daniel E Salazar | |||
| John T Brandt | |||
| P2860 | cites work | Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity | Q28174325 |
| Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease | Q28196661 | ||
| Regulation of platelet functions by P2 receptors | Q28290720 | ||
| Platelets in atherothrombosis | Q34986345 | ||
| Atherothrombosis and high-risk plaque: part I: evolving concepts | Q36259704 | ||
| Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders | Q39482244 | ||
| The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties | Q41906079 | ||
| Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. | Q46895618 | ||
| The disposition of prasugrel, a novel thienopyridine, in humans. | Q50700156 | ||
| Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. | Q51905748 | ||
| ??? | Q28200530 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| clopidogrel | Q410237 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 475-484 | |
| P577 | publication date | 2008-02-26 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel | |
| P478 | volume | 48 |
| Q57621041 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS |
| Q50089557 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. |
| Q58695080 | A Randomized Double-Blind Placebo-Controlled Trial to Evaluate Prophylactic Effect of Traditional Chinese Medicine Supplementing Qi and Hemostasis Formula on Gastrointestinal Bleeding after Percutaneous Coronary Intervention in Patients at High Risks |
| Q37788682 | A comparison of the metabolism of clopidogrel and prasugrel |
| Q37973114 | A comprehensive comparative review of adenosine diphosphate receptor antagonists |
| Q44904056 | A limited number of prescribed drugs account for the great majority of drug-drug interactions |
| Q34603772 | A population-based study of the drug interaction between proton pump inhibitors and clopidogrel |
| Q37995859 | Acute coronary syndromes: identifying the appropriate patient for prasugrel |
| Q55533621 | Adverse Risks Associated With Proton Pump Inhibitors: A Systematic Review. |
| Q89220120 | Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose |
| Q36441481 | Antiplatelet agents and proton pump inhibitors - personalizing treatment |
| Q36302146 | Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review |
| Q33948811 | Antiplatelet drug interactions with proton pump inhibitors |
| Q37914924 | Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents |
| Q22305927 | Antiplatelet resistance in stroke |
| Q36160606 | Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes |
| Q45995576 | Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination? |
| Q37798798 | Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. |
| Q46098828 | Assaying the efficacy of dual-antiplatelet therapy: use of a controlled-shear-rate microfluidic device with a well-defined collagen surface to track dynamic platelet adhesion |
| Q37831317 | Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. |
| Q37140633 | CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors |
| Q84974386 | Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding |
| Q36390258 | Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. |
| Q38177048 | Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors |
| Q38307535 | Clinical pharmacokinetics and pharmacodynamics of clopidogrel |
| Q37957037 | Clopidogrel and PPI interaction: clinically relevant or not? |
| Q24633087 | Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs |
| Q35959258 | Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? |
| Q33705305 | Clopidogrel and proton pump inhibitors: a new drug interaction? |
| Q37912178 | Clopidogrel pharmacogenetics: metabolism and drug interactions |
| Q37627874 | Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations |
| Q38008466 | Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications |
| Q35126153 | Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors |
| Q37629641 | Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. |
| Q57300220 | Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation |
| Q34458143 | Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. |
| Q43643259 | Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel |
| Q37697780 | Drug interaction between clopidogrel and proton pump inhibitors |
| Q34983154 | Drug-drug interaction between clopidogrel and the proton pump inhibitors. |
| Q44375151 | Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers |
| Q37770556 | Drug-drug interaction profiles of proton pump inhibitors |
| Q37407206 | Drug-drug interactions and their predictors: Results from Indian elderly inpatients. |
| Q42632671 | Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial |
| Q49833189 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. |
| Q37807398 | Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel |
| Q36493369 | Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome |
| Q37979178 | Emerging antiplatelet agents, differential pharmacology, and clinical utility |
| Q26998331 | Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy |
| Q30746761 | Factors affecting carisoprodol metabolism in pain patients using urinary excretion data |
| Q37885723 | Gastrointestinal effects of aspirin |
| Q43158045 | Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play? |
| Q37991382 | Genetic and non-genetic factors affecting the response to clopidogrel therapy. |
| Q37259929 | Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease |
| Q37907918 | Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists |
| Q36784692 | Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome |
| Q42961046 | Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study |
| Q53151801 | Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients. |
| Q38025446 | Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel |
| Q37452994 | Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor |
| Q42875458 | Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies |
| Q34174915 | Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes |
| Q45918033 | Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. |
| Q33561577 | Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent |
| Q45977708 | Interaction between clopidogrel and proton pump inhibitors. |
| Q42731681 | Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases |
| Q42723622 | Interaction between clopidogrel and proton-pump inhibitors |
| Q37641606 | Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans |
| Q45019665 | New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment |
| Q36754362 | Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study. |
| Q37786622 | Nonresponders to clopidogrel: pharmacokinetics and interactions involved. |
| Q38974392 | Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies |
| Q33902628 | Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor |
| Q60017632 | Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients |
| Q84009913 | Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI |
| Q35222839 | Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study |
| Q37562606 | P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. |
| Q37339517 | P2Y12 inhibitors in cardiovascular disease: focus on prasugrel |
| Q37151528 | Pharmacogenetic testing: Current Evidence of Clinical Utility |
| Q38117748 | Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists |
| Q27022254 | Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update |
| Q26852535 | Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy |
| Q38189810 | Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. |
| Q43288118 | Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor |
| Q51257153 | Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole. |
| Q37835616 | Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel |
| Q38151563 | Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. |
| Q37678656 | Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions |
| Q35204942 | Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study |
| Q37818331 | Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development |
| Q38012439 | Prasugrel is effective and safe for neurointerventional procedures |
| Q37641320 | Prasugrel: a critical comparison with clopidogrel. |
| Q37579188 | Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q93037397 | Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir |
| Q58598399 | Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface |
| Q51507688 | Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. |
| Q37630911 | Proton pump inhibitor and clopidogrel interaction: fact or fiction? |
| Q38136990 | Proton pump inhibitors and clopidogrel: an association to avoid? |
| Q33949498 | Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications |
| Q38011261 | Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? |
| Q41996131 | Proton-pump inhibitors: understanding the complications and risks |
| Q37540088 | Recent developments in clopidogrel pharmacology and their relation to clinical outcomes |
| Q38258270 | Resistance to antiplatelet drugs: what progress has been made? |
| Q37807524 | Resistance to aspirin and clopidogrel therapy. |
| Q37799470 | Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians |
| Q37837981 | Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction |
| Q37809630 | Review: Antiplatelet drugs: what comes next? |
| Q43749098 | Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel |
| Q42930308 | Safety and interactions of proton pump inhibitors: lessons learned in millions of patients |
| Q37738629 | Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents |
| Q51151977 | Switching from clopidogrel to prasugrel in patients having coronary stent implantation. |
| Q37986645 | The clinical relevance of the clopidogrel-proton pump inhibitor interaction. |
| Q51816112 | The discovery and development of prasugrel. |
| Q33763929 | The potential interaction between clopidogrel and proton pump inhibitors: a systematic review |
| Q37576116 | Thienopyridine therapy and risk for cardiovascular events in secondary prevention |
| Q37914050 | Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance |
| Q37838124 | Thienopyridines in Acute Coronary Syndrome |
| Q57462435 | Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016 |
| Q37704842 | What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel |
| Q84707943 | [Drug interactions in geriatric medicine] |
| Q26829973 | 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat |
| Q22242895 | ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el |
Search more.